Evidence map›Paper›PMID 37873386›Full record

ArticlemedRxiv : the preprint server for health sciences2023

The tumor multi-omic landscape of endometrial cancers developed on a germline genetic background of adiposity.

George Richenberg, Amy Francis, Carina N Owen, Victoria Gray, Timothy Robinson, Aurélie Ag Gabriel, Kate Lawrenson, Emma J Crosbie, Joellen M Schildkraut, James D Mckay and 4 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 4 countries.

George RichenbergMRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.
Amy FrancisMRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.
Carina N OwenMRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.
Victoria GrayMRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.
Timothy RobinsonMRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.
Aurélie Ag GabrielDepartment of Oncology, Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland.
Kate LawrensonWomen's Cancer Research Program at the Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Emma J CrosbieDivision of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
Joellen M SchildkrautDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
James D MckayGenomic Epidemiology Branch, International Agency for Research on Cancer/World Health Organization (IARC/WHO), Lyon, France.
Tom R GauntMRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.
Caroline L ReltonMRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.
Emma E VincentMRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.
Siddhartha P KarMRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.
University of Bristol · GBUniversity Hospitals Bristol NHS Foundation Trust · GBCedars-Sinai Medical Center · USCentre international de recherche sur le cancer · FREmory University · USLudwig Cancer Research · CHUniversity of Cambridge · GBUniversity of Manchester · GB

Funding

Genomic and Transcriptomic Analysis of Breast and Ovarian CancersR01CA211574 · NCI · UNIVERSITY OF VIRGINIA · PI GAYTHER, SIMON ANDREW, SCHILDKRAUT, JOELLEN M. · 2018 to 2022
$3.1M
Common biology underlying pleiotropic breast, prostate and ovarian cancer risk lociR01CA259058 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI MATTHEW L FREEDMAN, Simon Andrew Gayther · 2022 to 2026
$2.5M
Medical Research Council MR/T043202/1NCI NIH HHS R01 CA211574NCI NIH HHS R01 CA259058
6 · The paper itself

Abstract

High body mass index (BMI) is a causal risk factor for endometrial cancer but the tumor molecular mechanisms affected by adiposity and their therapeutic relevance remain poorly understood. Here we characterize the tumor multi-omic landscape of endometrial cancers that have developed on a background of lifelong germline genetic exposure to elevated BMI. We built a polygenic score (PGS) for BMI in women using data on independent, genome-wide significant variants associated with adult BMI in 434,794 women. We performed germline (blood) genotype quality control and imputation on data from 354 endometrial cancer cases from The Cancer Genome Atlas (TCGA). We assigned each case in this TCGA cohort their genetically predicted life-course BMI based on the BMI PGS. Multivariable generalized linear models adjusted for age, stage, microsatellite status and genetic principal components were used to test for associations between the BMI germline PGS and endometrial cancer tumor genome-wide genomic, transcriptomic, proteomic, epigenomic and immune traits in TCGA. High BMI germline PGS was associated with (i) upregulated tumor gene expression in the

Identifiers

PMID37873386
PMCPMC10592984
OpenAlexW4387494807

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.